Natural killer T cell-mediated antitumor immune responses and their clinical applications

Cancer Science

Volumn 97, Issue 9, 2006, Pages 807-812

  Seino, Ken Ichiro ^a,b   Motohashi, Shinichiro ^c   Fujisawa, Takehiko ^c   Nakayama, Toshinori ^c   Taniguchi, Masaru ^a  

^a RIKEN Center for Integrative Medical Sciences   (Japan)

^b ST MARIANNA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c CHIBA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CD1D ANTIGEN; CERAMIDE; GALACTOSE; GLYCOLIPID; T LYMPHOCYTE RECEPTOR ALPHA CHAIN;

CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL TYPE; CELLULAR IMMUNITY; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; HUMAN; IMMUNOREGULATION; INNATE IMMUNITY; LYMPHOCYTE FUNCTION; LYMPHOCYTE SUBPOPULATION; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE ACTIVATION; TH1 CELL; TUMOR IMMUNITY;

ANIMALS; ANTIGENS, CD1; CELL COMMUNICATION; CLINICAL TRIALS; DENDRITIC CELLS; GALACTOSYLCERAMIDES; HUMANS; IMMUNOTHERAPY; KILLER CELLS, NATURAL; LYMPHOCYTE ACTIVATION; LYMPHOCYTE SUBSETS; MICE; NEOPLASMS;

EID: 33746601264     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2006.00257.x     Document Type: Review

References (51)

1. Godfrey DI, MacDonald HR, Kronenberg M, Smyth MJ, Van Kaer L. NKT cells: what's in a name? Nat Rev Immunol 2004; 4: 231-7.
2. Kawano T, Cui J, Koezuka Y et al. CD1d-restricted and TCR-mediated activation of Valpha14 NKT cells by glycosylceramides. Science 1997; 278: 1626-9.
3. Taniguchi M, Harada M, Kojo S, Nakayama T, Wakao H. The regulatory role of Valpha14NKT cells in innate and acquired immune response. Annu Rev Immunol 2003; 21: 483-513.
4. Cui J, Shin T, Kawano T et al. Requirement for Valpha14 NKT cells in IL-12-mediated rejection of tumors. Science 1997; 278: 1623-6.
5. Mendiratta SK, Martin WD, Hong S, Boesteanu A, Joyce S, Van Kaer L. CD1d1 mutant mice are deficient in natural T cells that promptly produce IL-4. Immunity 1997; 6: 469-77.
6. Kawano T, Cui J, Koezuka Y et al. Natural killer-like nonspecific tumor cell lysis mediated by specific ligand-activated Valpha14 NKT cells. Proc Natl Acad Sci USA 1998; 95: 5690-3.
7. + V alpha 24NKT cells induces in vitro and in vivo apoptosis of human acute myeloid leukemia cells. Blood 2001; 97: 2067-74.
8. Nakagawa R, Nagafune I, Tazunoki Y et al. Mechanisms of the antimetastatic effect in the liver and of the hepatocyte injury induced by alpha-galactosylceramide in mice. J Immunol 2001; 166: 6578-84.
9. Taniguchi M, Seino K, Nakayama T. The NKT cell system: Bridging innate and acquired immunity. Nat Immunol 2003; 4: 1164-5.
10. Miyamoto K, Miyake S, Yamamura T. A synthetic glycolipid prevents autoimmune encephalomyelitis by inducing TH2 bias of natural killer T cells. Nature 2001; 413: 531-4.
11. Schmieg J, Yang G, Franck RW, Tsuji M. Superior protection against malaria and melanoma metastases by a C-glycoside analogue of the natural killer T cell ligand alpha-Galactosylceramide. J Exp Med 2003; 198: 1631-41.
12. Koch M, Stronge VS, Shepherd D et al. The crystal structure of human CD1d with and without alpha-galactosylceramide. Nat Immunol 2005; 6: 819-26.
13. Zajonc DM, Cantu C 3rd, Mattner J et al. Structure and function of a potent agonist for the semi-invariant natural killer T cell receptor. Nat Immunol 2005; 6: 810-18.
14. Kawano T, Nakayama T, Kamada N et al. Antitumor cytotoxicity mediated by ligand-activated human V alpha24 NKT cells. Cancer Res 1999; 59: 5102-5.
15. Kitamura H, Iwakabe K, Yahata T et al. The natural killer T (NKT) cell ligand alpha-galactosylceramide demonstrates its immunopotentiating effect by inducing interleukin (IL)-12 production by dendritic cells and IL-12 receptor expression on NKT cells. J Exp Med 1999; 189: 1121-8.
16. +NKT cells: Stimulation of IL-12 production by antigen-presenting cells in the innate immune system. J Immunol 1999; 163: 93-101.
17. + T cells and natural killer cells is essential for the antimetastatic effect of alpha-galactosylceramide. Blood 2002; 99: 1259-66.
18. Hayakawa Y, Takeda K, Yagita H et al. Critical contribution of IFN-gamma and NK cells, but not perforin-mediated cytotoxicity, to anti-metastatic effect of alpha-galactosylceramide. Eur J Immunol 2001; 31: 1720-7.
19. Brigl M, Bry L, Kent SC, Gumperz JE, Brenner MB. Mechanism of CD1d-restricted natural killer T cell activation during microbial infection. Nat Immunol 2003; 4: 1230-7.
20. Fujii S, Liu K, Smith C, Bonito AJ, Steinman RM. The linkage of innate to adaptive immunity via maturing dendritic cells in vivo requires CD40 ligation in addition to antigen presentation and CD80/86 costimulation. J Exp Med 2004; 199: 1607-18.
21. Fujii S, Shimizu K, Smith C, Bonifaz L, Steinman RM. Activation of natural killer T cells by alpha-galactosylceramide rapidly induces the full maturation of dendritic cells in vivo and thereby acts as an adjuvant for combined CD4 and CD8 T cell immunity to a coadministered protein. J Exp Med 2003; 198: 267-79.
22. Smyth MJ, Cretney E, Takeda K et al. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) contributes to interferon gamma-dependent natural killer cell protection from tumor metastasis. J Exp Med 2001; 193: 661-70.
23. Smyth MJ, Thia KY, Street SE et al. Differential tumor surveillance by natural killer (NK) and NKT cells. J Exp Med 2000; 191: 661-8.
24. Smyth MJ, Crowe NY. Godfrey DI. NK cells and NKT cells collaborate in host protection from methylcholanthrene-induced fibrosarcoma. Int Immunol 2001; 13: 459-63.
25. Gumperz JE, Roy C, Makowska A et al. Murine CD1d-restricted T cell recognition of cellular lipids. Immunity 2000; 12: 211-21.
26. Zhou D, Mattner J, Cantu C 3rd et al. Lysosomal glycosphingolipid recognition by NKT cells. Science 2004; 306: 1786-9.
27. Crowe NY, Coquet JM, Berzins SP et al. Differential antitumor immunity mediated by NKT cell subsets in vivo. J Exp Med 2005; 202: 1279-88.
28. Seino K, Taniguchi M. Functionally distinct NKT cell subsets and subtypes. J Exp Med 2005; 202: 1623-6.
29. Azuma T, Takahashi T, Kunisato A, Kitamura T, Hirai H. Human CD4+ CD25+ regulatory T cells suppress NKT cell functions. Cancer Res 2003; 63: 4516-20.
30. + T cells responding to serologically defined autoantigens suppress antitumor immune responses. Proc Natl Acad Sci USA 2003; 100: 10902-6.
31. Motohashi S, Kobayashi S, Ito T et al. Preserved IFN-gamma production of circulating Valpha24 NKT cells in primary lung cancer patients. Int J Cancer 2002; 102: 159-65.
32. Tahir SM, Cheng O, Shaulov A et al. Loss of IFN-gamma production by invariant NK T cells in advanced cancer. J Immunol 2001; 167: 4046-50.
33. Yanagisawa K, Seino K, Ishikawa Y, Nozue M, Todoroki T, Fukao K. Impaired proliferative response of V alpha 24 NKT cells from cancer patients against alpha-galactosylceramide. J Immunol 2002; 168: 6494-9.
34. Fujii S, Shimizu K, Klimek V, Geller MD, Nimer SD, Dhodapkar MV. Severe and selective deficiency of interferon-gamma-producing invariant natural killer T cells in patients with myelodysplastic syndromes. Br J Haematol 2003; 122: 617-22.
35. Dhodapkar MV, Geller MD, Chang DH et al. A reversible defect in natural killer T cell function characterizes the progression of premalignant to malignant multiple myeloma. J Exp Med 2003; 197: 1667-76.
36. Terabe M, Matsui S, Noben-Trauth N et al. NKT cell-mediated repression of tumor immunosurveillance by IL-13 and the IL-4R-STAT6 pathway. Nat Immunol 2000; 1: 515-20.
37. Terabe M, Matsui S, Noben-Trauth N et al. TGF-beta production and myeloid cell are an effector mechanism through which CD1d-restricted T cells block CTL-mediated tumor immunosurveillance: Abrogation prevents tumor recurrence. J Exp Med 2003; 198: 1741-52.
38. Terabe M, Swann J, Ambrosino E et al. A nonclassical non-Valpha14Jalpha18 CD1d-restricted (type II) NKT cell is sufficient for down-regulation of tumor immunosurveillance. J Exp Med 2005; 202: 1627-33.
39. Terabe M, Khanna C, Bose S et al. CD1d-restricted natural killer T cells can down-regulate tumor immunosurveillance independent of interleukin-4 receptor-signal transducer and activator of transcription 6 or transforming growth factor-beta. Cancer Res 2006; 66: 3869-75.
40. + NKT cells by repeated stimulation with KRN7000. J Immunol Meth 2004; 285: 197-214.
41. van der Vliet HJ, Nishi N, Koezuka Y et al. Potent expansion of human natural killer T cells using alpha-galactosylceramide (KRN7000) -loaded monocyte-derived dendritic cells, cultured in the presence of IL-7 and IL-15. J Immunol Meth 2001; 247: 61-72.
42. + NKT cells activated by alpha-glycosylceramide-pulsed monocyte-derived dendritic cells. J Immunol 2000; 164: 4458-64.
43. Metelitsa LS, Naidenko OV, Kant A et al. Human NKT cells mediate antitumor cytotoxicity directly by recognizing target cell CD1d with bound ligand or indirectly by producing IL-2 to activate NK cells. J Immunol 2001; 167: 3114-22.
44. Gumperz JE, Miyake S, Yamamura T, Brenner MB. Functionally distinct subsets of CD1d-restricted natural killer T cells revealed by CD1d tetramer staining. J Exp Med 2002; 195: 625-36.
45. Giaccone G, Punt CJ, Ando Y et al. A phase I study of the natural killer T-cell ligand alpha-galactosylceramide (KRN7000) in patients with solid tumors. Clin Cancer Res 2002; 8: 3702-9.
46. Fujii S, Shimizu K, Kronenberg M, Steinman RM. Prolonged IFN-gamma-producing NKT response induced with alpha-galactosylceramide-loaded DCs. Nat Immunol 2002; 3: 867-74.
47. Toura I, Kawano T, Akutsu Y, Nakayama T, Ochiai T, Taniguchi M. Cutting edge: Inhibition of experimental tumor metastasis by dendritic cells pulsed with alpha-galactosylceramide. J Immunol 1999; 163: 2387-91.
48. Akutsu Y, Nakayama T, Harada M et al. Expansion of lung Valpha14 NKT cells by administration of alpha-galactosylceramide-pulsed dendritic cells. Jpn J Cancer Res 2002; 93: 397-403.
49. Ishikawa A, Motohashi S, Ishikawa E et al. A phase I study of alpha-galactosylceramide (KRN7000)-pulsed dendritic cells in patients with advanced and recurrent non-small cell lung cancer. Clin Cancer Res 2005; 11: 1910-17.
50. + natural killer T-cell activation by alpha-galactosylceramide. Int J Cancer 2005; 117: 265-73.
51. + NKT cells in human subjects results in highly coordinated secondary activation of acquired and innate immunity. Blood 2004; 103: 383-9.